These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38334216)

  • 1. Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell-Based Therapy in Ovarian Cancer.
    Andele PK; Palazzolo S; Corona G; Caligiuri I; Kamensek U; Cemazar M; Canzonieri V; Rizzolio F
    Adv Healthc Mater; 2024 Jun; 13(15):e2304206. PubMed ID: 38334216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
    Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
    J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
    Nieman KM; Kenny HA; Penicka CV; Ladanyi A; Buell-Gutbrod R; Zillhardt MR; Romero IL; Carey MS; Mills GB; Hotamisligil GS; Yamada SD; Peter ME; Gwin K; Lengyel E
    Nat Med; 2011 Oct; 17(11):1498-503. PubMed ID: 22037646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
    Cho H; Lai TC; Kwon GS
    J Control Release; 2013 Feb; 166(1):1-9. PubMed ID: 23246471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
    Sui M; Chen F; Chen Z; Fan W
    Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
    Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
    J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
    Okugawa K; Kobayashi H; Hirakawa T; Sonoda T; Ogura T; Nakano H
    J Cancer Res Clin Oncol; 2004 Mar; 130(3):178-86. PubMed ID: 14655049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
    Kim JE; Park YJ
    Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Iyoshi S; Yoshihara M; Nakamura K; Sugiyama M; Koya Y; Kitami K; Uno K; Mogi K; Tano S; Tomita H; Kajiwara K; Taki M; Yamaguchi S; Nawa A; Kajiyama H
    Int J Cancer; 2021 Dec; 149(11):1961-1972. PubMed ID: 34469585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
    Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
    J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
    Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
    Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
    Liu Y; Ng Y; Toh MR; Chiu GNC
    J Control Release; 2015 Dec; 220(Pt A):438-446. PubMed ID: 26551345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
    Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.
    Au Yeung CL; Co NN; Tsuruga T; Yeung TL; Kwan SY; Leung CS; Li Y; Lu ES; Kwan K; Wong KK; Schmandt R; Lu KH; Mok SC
    Nat Commun; 2016 Mar; 7():11150. PubMed ID: 27021436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
    Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
    Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts.
    Pu C; Chang S; Sun J; Zhu S; Liu H; Zhu Y; Wang Z; Xu RX
    Mol Pharm; 2014 Jan; 11(1):49-58. PubMed ID: 24237050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.
    Mukherjee A; Chiang CY; Daifotis HA; Nieman KM; Fahrmann JF; Lastra RR; Romero IL; Fiehn O; Lengyel E
    Cancer Res; 2020 Apr; 80(8):1748-1761. PubMed ID: 32054768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.